Table 2.
Source of data | Sex/age (yr) | Date of episode | Site of oedema | Dose (mL) | Adverse events | Treatment for side effects | Time until resolution (hours) | Length of stay in hospital (hours) | CTCAE grade10 |
---|---|---|---|---|---|---|---|---|---|
South Africa | F/31 | 05/2017 | Upper airway | 800 | Urticaria | Antihistamine | 24 | 72 | 2 |
M/40 | 12/2015 | Upper airway | 800 | Anaphylaxis | Adrenaline, antihistamine, corticosteroid, intubation | 46 | 125 | 4 | |
Iran | F/23a | 2015 | Abdominal | 200 | Urticaria and dyspnoea | Steroids, cetirizine, adrenaline | 0.5 | 5 | 3 |
F/40 | 05/2017 | Upper airway | 900 | Urticaria | Hydroxyzine | – | 72 | 2 | |
08/2017 | Upper airway | 1350 | Urticaria | Hydroxyzine | 5 | 12 | 2 |
This patient had subsequent FFP-treated HAE acute episodes; receipt of premedication with antihistamines resulted in no subsequent TEAE